PLIVA Explores Impact of Current EU Guidelines on Clinical Evaluation of Modified Release Drugs
London, United Kingdom, November 24, 2017 --(PR.com)-- SMi Group has announced that Pavel Farkas, Senior Director for Biopharmaceutics Clinical Development at PLIVA, will be joining the speaker line-up for the 15th annual Controlled Release Delivery conference in London next March.
With recent reports predicting the oral release drug delivery technology market to reach $50B by 2027, as well as a surge of new controlled-release technologies in phase to be commercialized in next few years, the need to understand the regulations surrounding drug delivery systems has become more significant than ever.
Speaking on Day 1 of the conference, Pavel's presentation will focus on the impact of the current EU Guidelines EMA/CPMP/EWP/280/96/Corr 1 on the pharmacokinetic and clinical evaluation of modified release dosage forms of generic drug products. This not-to-be-missed Keynote Address will explore:
purposes of the guideline and general considerations
types of oral modified release products from the biopharmaceutics perspective
general rules for types of required bioequivalence studies
primary PK parameters for demonstration of bioequivalence and their evaluation in single-dose and multiple-dose studies
a case-by-case approach
More details about the presentation as well as the full speaker line-up for the conference can be found on www.controlledreleasedelivery.com/prcom.
Building on the success of previous events, SMi has announced the return of its 15th annual Controlled Release Delivery, taking place on 21st and 22nd March in London, UK.
Now running for 15 years, Controlled Release Delivery 2018 aims to explore and to understand innovations in oral-lipid based and abuse deterrent formulations, nanoparticles and nanotechnologies, taste-masking and controlled release approaches, 3D printed dosage forms and functional film coats.
For those interested to attend, registration is now live on the event website and there is currently an Early Bird Discount of £400 which expires on 30 November 2017.
15th Controlled Release Delivery Conference
21-22 March 2018
Copthorne Tara Hotel, London, UK
For delegate registration enquiries, contact Kieran Ronaldson on kronaldson@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.
With recent reports predicting the oral release drug delivery technology market to reach $50B by 2027, as well as a surge of new controlled-release technologies in phase to be commercialized in next few years, the need to understand the regulations surrounding drug delivery systems has become more significant than ever.
Speaking on Day 1 of the conference, Pavel's presentation will focus on the impact of the current EU Guidelines EMA/CPMP/EWP/280/96/Corr 1 on the pharmacokinetic and clinical evaluation of modified release dosage forms of generic drug products. This not-to-be-missed Keynote Address will explore:
purposes of the guideline and general considerations
types of oral modified release products from the biopharmaceutics perspective
general rules for types of required bioequivalence studies
primary PK parameters for demonstration of bioequivalence and their evaluation in single-dose and multiple-dose studies
a case-by-case approach
More details about the presentation as well as the full speaker line-up for the conference can be found on www.controlledreleasedelivery.com/prcom.
Building on the success of previous events, SMi has announced the return of its 15th annual Controlled Release Delivery, taking place on 21st and 22nd March in London, UK.
Now running for 15 years, Controlled Release Delivery 2018 aims to explore and to understand innovations in oral-lipid based and abuse deterrent formulations, nanoparticles and nanotechnologies, taste-masking and controlled release approaches, 3D printed dosage forms and functional film coats.
For those interested to attend, registration is now live on the event website and there is currently an Early Bird Discount of £400 which expires on 30 November 2017.
15th Controlled Release Delivery Conference
21-22 March 2018
Copthorne Tara Hotel, London, UK
For delegate registration enquiries, contact Kieran Ronaldson on kronaldson@smi-online.co.uk. For media enquiries, contact Honey de Gracia at hdegracia@smi-online.co.uk.
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk.
Contact
SMi Group
Honey de Gracia
+44 (0) 20 7827 6048
http://www.controlledreleasedelivery.com/prcom
Contact
Honey de Gracia
+44 (0) 20 7827 6048
http://www.controlledreleasedelivery.com/prcom
Categories